Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Qiagen on Wednesday afternoon reported preliminary second quarter financial results ahead of its full Q2 earnings release next week, and said that it is adjusting its full-year financial targets downward due to lower-than-expected sales of i

PerkinElmer said after the close of the market on Monday that its total revenues in the second quarter grew 3 percent year over year but missed the consensus Wall Street estimate.

Illumina reported after the close of the market on Monday that its second quarter 2019 revenues grew 1 percent year over year.

China's National Medical Products Administration (NMPA) recently extended approval of the Roche Cobas EGFR Mutation Test v2 to include the use of plasma samples for the detection of EGFR mutations in patients with non-small cell lung cancer,

RNAi therapeutics firm Alnylam Pharmaceuticals and consumer genetics firm 23andMe will offer free genetic test kits to first-degree family members of 23andMe customers who have a TTR variant known to cause hereditary amyloidosis.

Illumina will bring its genomics startup incubator to the UK next year.

The Parkinson's Foundation and Fulgent Genetics announced recently that they have begun a collaboration on a new genetic testing initiative for Parkinson's disease patients. The group said that the initiative, called PD GENEration: Mapping t

Abbott recently said that its Diagnostics business revenues grew 2 percent year over year in the second quarter, while its total revenues were up 3 percent.

PathogenDx has entered into a strategic partnership with Nationwide Laboratory Services for fungal testing of dermatology and podiatry samples.

Danaher recently reported a 4 percent year-over-year increase in its second quarter revenues, which included a 6 percent rise in life sciences segment revenues and a rise of almost 5 percent in its diagnostics segment.